MedTrace Logo

Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma

NCT02848794 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-06-16

No results posted yet for this study

Summary

The study is aimed to evaluate the efficacy and safety of Apatinib and Irinotecan in patients with recurrent high-grade glioma.

Conditions

  • High-grade Glioma

Interventions

DRUG

Apatinib and Irinotecan

Patients were administered at apatinib (850mg po qd) and irinotecan(125mg/m2 d1,8) intravenously every three weeks for up to 6 cycles.Maintenance apatinib (500mg po qd) was administered until disease progression or unacceptable toxicity.

Sponsors & Collaborators

  • Shandong Cancer Hospital and Institute

    collaborator OTHER

  • The Affiliated Hospital of Qingdao University

    collaborator OTHER

  • Yankuang Group General Hospital

    collaborator UNKNOWN

  • Lianyungang Hospital Affiliated Bengbu Medical College

    collaborator OTHER

  • Suzhou Kowloon Hospital

    collaborator UNKNOWN

  • The First People's Hospital of Lianyungang

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02848794 on ClinicalTrials.gov